ValiRx plc (LON:VAL – Get Free Report)’s stock price dropped 2.4% during mid-day trading on Tuesday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.10 ($0.03). Approximately 2,947,279 shares changed hands during mid-day trading, an increase of 182% from the average daily volume of 1,043,736 shares. The stock had previously closed at GBX 2.15 ($0.03).
ValiRx Trading Down 1.7 %
The firm has a market cap of £2.28 million, a price-to-earnings ratio of -93.50 and a beta of 0.59. The business has a 50 day moving average of GBX 1.84 and a 200 day moving average of GBX 2.53. The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than ValiRx
- What does consumer price index measure?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is the Australian Securities Exchange (ASX)
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
